NCT01468922View on ClinicalTrials.gov

Pazopanib and ARQ 197 for Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 23, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

February 11, 2016

Conditions
Solid Tumor
Interventions
DRUG

Pazopanib

Vascular endothelial growth factor (VEGFR) inhibitor

DRUG

ARQ 197

Hepatocyte growth factor receptor (mesenchymal-epithelial transition factor \[c-MET\]) inhibitor

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01468922 - Pazopanib and ARQ 197 for Advanced Solid Tumors | Biotech Hunter | Biotech Hunter